Fig. 6From: Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysisPersistency chart (proportional hazards model) for octreotide vs lanreotide, patients with 180-day washout period (n = 663). Survival indicates probability of patients continuing treatment. Hazard ratio (risk of discontinuing treatment) for octreotide vs lanreotide: 1.381; p = 0.011Back to article page